Affiliation:
1. Department of Radiology Peking University First Hospital Beijing China
2. Beijing Smart Tree Medical Technology Co. Ltd Beijing China
3. Department of Nuclear Medicine Sun Yat‐Sen University Cancer Center Guangzhou Guangdong China
4. State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China
5. School of Basic Medical Sciences Capital Medical University Beijing China
Abstract
BackgroundDeep learning for diagnosing clinically significant prostate cancer (csPCa) is feasible but needs further evaluation in patients with prostate‐specific antigen (PSA) levels of 4–10 ng/mL.PurposeTo explore diffusion‐weighted imaging (DWI), alone and in combination with T2‐weighted imaging (T2WI), for deep‐learning‐based models to detect and localize visible csPCa.Study TypeRetrospective.PopulationOne thousand six hundred twenty‐eight patients with systematic and cognitive‐targeted biopsy‐confirmation (1007 csPCa, 621 non‐csPCa) were divided into model development (N = 1428) and hold‐out test (N = 200) datasets.Field Strength/SequenceDWI with diffusion‐weighted single‐shot gradient echo planar imaging sequence and T2WI with T2‐weighted fast spin echo sequence at 3.0‐T and 1.5‐T.AssessmentThe ground truth of csPCa was annotated by two radiologists in consensus. A diffusion model, DWI and apparent diffusion coefficient (ADC) as input, and a biparametric model (DWI, ADC, and T2WI as input) were trained based on U‐Net. Three radiologists provided the PI‐RADS (version 2.1) assessment. The performances were determined at the lesion, location, and the patient level.Statistical TestsThe performance was evaluated using the areas under the ROC curves (AUCs), sensitivity, specificity, and accuracy. A P value <0.05 was considered statistically significant.ResultsThe lesion‐level sensitivities of the diffusion model, the biparametric model, and the PI‐RADS assessment were 89.0%, 85.3%, and 90.8% (P = 0.289–0.754). At the patient level, the diffusion model had significantly higher sensitivity than the biparametric model (96.0% vs. 90.0%), while there was no significant difference in specificity (77.0%. vs. 85.0%, P = 0.096). For location analysis, there were no significant differences in AUCs between the models (sextant‐level, 0.895 vs. 0.893, P = 0.777; zone‐level, 0.931 vs. 0.917, P = 0.282), and both models had significantly higher AUCs than the PI‐RADS assessment (sextant‐level, 0.734; zone‐level, 0.863).Data ConclusionThe diffusion model achieved the best performance in detecting and localizing csPCa in patients with PSA levels of 4–10 ng/mL.Evidence Level3Technical EfficacyStage 2
Funder
Capital Health Research and Development of Special Fund
Subject
Radiology, Nuclear Medicine and imaging